LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

The Board is pleased to announce the unaudited consolidated financial results of the Group for the six months ended June 30, 2025, together with the comparative figures for the six months ended June 30, 2024 as below.

The interim results of the Group for the six months ended June 30, 2025 have been reviewed by the Audit Committee and by BDO China Shu Lun Pan Certified Public Accountants LLP, the independent auditor of the Group, in accordance with the China Certified Public Accountant Review Standard No. 2101 "Review of interim financial information performed by the independent auditor of the entity" issued by the Chinese Institute of Certified Public Accountants.

FINANCIAL HIGHLIGHTS

– Revenue increased by 32.4% from RMB249.1 million for the six months ended June 30, 2024 to RMB329.7 million for the six months ended June 30, 2025.

– Gross profit increased by 25.4% from RMB226.7 million for the six months ended June 30, 2024 to RMB284.3 million for the six months ended June 30, 2025.

– Research and development expenses increased by 17.0% from RMB21.7 million for the six months ended June 30, 2024 to RMB25.4 million for the six months ended June 30, 2025.

– Net profit attributable to shareholders of the parent company increased by 29.8% from RMB140.2 million for the six months ended June 30, 2024 to RMB182.0 million for the six months ended June 30, 2025.

– The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025 (six months ended June 30, 2024: nil).

Note:

Certain amounts and percentage figures included in this announcement have been subject to rounding. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them. Any discrepancies in any table or chart between the total shown and the sum of the amounts listed are due to rounding.

BUSINESS REVIEW

Over the years, the Group has been focusing on the research and development, manufacture and commercialization of heart disease interventional medical devices. We have over 20 years of industry experience in the traditional metal medical devices, and we have been successfully practicing degradability of medical devices in recent years, and at the same time, the Company is exploring the frontier fields of the heart valves, cardiac mechanical circulatory support, atrial septal puncture and other medical devices. As a leader in the interventional medical devices industry in China, we will continue to provide safe, effective, innovative and comprehensive medical solutions in terms of breadth and depth.

As of the date of this announcement, we had a total of 30 marketed occluders, heart valves and accessory products, four products under registration review and preparation for registration and 28 product candidates in various stages of research and development such as occluders, heart valves and procedural accessories and mechanical circulatory support. The following chart summarizes the development status of our product portfolio up to the date of this announcement:

Product		Pre-clinical	Clinical Trial	Registration	Commercialization
Atrial septal defect ("**ASD**") occluder	MemoPart® ASD occluder (double-rivet)				Commercialized
	MemoPart® ASD occluder (single-rivet)				Commercialized
	MemoCarna® oxide coating ASD occluder with single-rivet				Commercialized
				Obtained the CE certificate	
	MemoSorb® biodegradable ASD occluder ★				Commercialized
Ventricular septal defect ("**VSD**") occluder	MemoPart® VSD occluder (double-rivet)				Commercialized
	MemoPart® VSD occluder (single-rivet)				Commercialized
	MemoCarna® oxide coating VSD occluder with single-rivet				Commercialized
				Obtained the CE certificate	
	MemoSorb® fully-degradable occluder systems ★				Commercialized
			Preparation for initiating of overseas clinical trials		

Product		Pre-clinical	Clinical Trial	Registration	Commercialization
Patent ductus arteriosus ("**PDA**") occluder	MemoPart® PDA occluder (double-rivet)				**Commercialized**
	MemoPart® PDA occluder (single-rivet)				**Commercialized**
	MemoCarna® oxide coating PDA occluder				**Commercialized**
				CE registration review in progress	
	MemoSorb® biodegradable PDA occluder		**Clinical preparation stage**		
Patent foramen ovale ("**PFO**") occluder	MemoPart® PFO occlude (double-rivet/single-rivet)				**Commercialized**
	MemoSorb® oxide coating PFO occluder ★			**Preparation for registration materials**	
	MemoSorb® biodegradable PFO occluder ★				**Commercialized**
	NeoSorb® bioabsorbable PFO occluder		**Mass clinical**		
Left atrial appendage ("**LAA**") occluder	MemoLefort® LAA occluder system				**Commercialized**
	Bio-Lefort® biodegradable LAA occluder ★		**Mass clinical**		
Aortic and peripheral occluders	Biodegradable aortic occluder ★		**FIM**		
	Aortic embolization occluder ★		**Mass clinical**		
	Peripheral hydrogel spring coil		**Animal test**		
	Biodegradable vascular plug ★	Design stage			
	Cross-linked reinforcement system of abdominal aortic aneurysm	Design stage			
Aortic valve products	ScienCrown® transcatheter aortic valve replacement ("**TAVR**") system ★				**Commercialized**
			CE animal tests		
	ScienMelon® artificial heart valve with polymer leaflets for transcatheter implantation ★		**Animal test**		
	ScienChute® transcatheter aortic valve stenosis therapy system	Design stage			
	ScienChute® pulsed acoustical generator	Design stage			
	Transcatheter aortic valve system (regurgitation indication TAVR)		**Animal test**		
Mitral valve products	MemoChord® transapical mitral valve repair system (chordal) ("**TMVCRS**")		**FIM**		
	MemoClip-A® transapical mitral valve clip repair ("**TMVr-A**") system ★		**Mass clinical**		
	MemoClip-F® transfemoral mitral valve clip repair ("**TMVr-F**") system		**Clinical preparation stage**		
	Transcatheter mitral valve replacement ("**TMVR**") system		**Animal test**		

Product		Pre-clinical	Clinical Trial	Registration	Commercialization
Atrial septal puncture and procedural accessories	RF-Lance® radiofrequency puncture devices ★	Commercialized			
	RF-Lance® disposable radiofrequency atrial septal puncture needles ★	Commercialized			
	Disposable atrial septal puncture system	Commercialized			
	MemoPart® interventional delivery system	Commercialized			
	GuiBend® integrated interventional delivery system	Commercialized			
	GuiFinder® occluder delivery system	Commercialized			
	GuiFlex® integrated interventional delivery sheath	Commercialized			
	Gruiser® interventional delivery system	Commercialized			
	G-Cruiser® interventional delivery system	Commercialized			
	MemoPart® snare	Commercialized			
	Multiple-loop snare	Commercialized			
	SimoMelon® balloon dilatation catheter for aortic valve ★	Commercialized			
	Disposable introducing sheath	Commercialized			
	Thrombus protection device	Clinical preparation stage			
	StarCross® disposable delivery sheath	Preparation for registration materials			
	Vascular closure device system	Mass clinical			
	Transvalvular guide wires	Commercialized			
	Super stiff guidewire	Supplementary stage of NMPA registration			
	Interventional guide wires	Supplementary stage of NMPA registration			
	Biodegradable LAA delivery system	Commercialized			
	Ultrasound contrast injection device	Design stage			

Product		Pre-clinical	Clinical Trial	Registration	Commercialization
Interatrial shunt device	Interatrial shunt device I	FIM			
	Interatrial shunt device II (biodegradable)	Animal test			
	FireyDeva® interatrial shunt device III (radiofrequency ablation shunt device)	Animal test			
	FireyDeva® radiofrequency ablation device (device)	Animal test			
Mechanical circulatory support products	Transcatheter left ventricular support device ★	Animal test			
	Coronary protection left ventricular support system ★	Design stage			
	Small diameter transcatheter left ventricular support system ★	Design stage			
Hypertensive device treatment products	Pulmonary artery radiofrequency ablation catheter	Design stage			
	Ultrasonic greater splanchnic nerve ablation catheter	Animal test			

Note:

★: *Key projects of the Company*

The business segments of the Company maintained a sound development trend overall, achieving stable growth in its revenue. For the six months ended June 30, 2025, the Company achieved revenue of RMB329.7 million, representing a period-on-period increase of 32.4% from the six months ended June 30, 2024; net profit attributable to shareholders of the parent company of RMB182.0 million for the six months ended June 30, 2025, representing a period-on-period increase of 29.8% from the six months ended June 30, 2024; net cash flows generated from operating activities of RMB166.8 million for the six months ended June 30, 2025, representing a period-on-period increase of 61.2% from the six months ended June 30, 2024. As of June 30, 2025, the total assets of the Group were RMB2,279.1 million, representing an increase of 9.4% from the beginning of the Reporting Period, and the net assets were RMB1,973.2 million, representing a decrease of 1.2% from the beginning of the Reporting Period.

CHD Occluder Products

As at the date of this announcement, the Group owned 11 commercially available CHD occluder products, among which, MemoCarna® III oxide coating single-rivet occluder series products have fast become the backbone of the CHD occluder products business after its approval for marketing in 2020. Upon the MemoSorb® IV fully-degradable occluder systems obtaining its approval for marketing in 2022, it was pleasing to see that MemoSorb® IV biodegradable ASD occlude products obtained the NMPA medical device registration certificate in August 2024. These two kinds of products have been rapidly commercialized, providing more options for clinical surgery for CHD and becoming the Group's flagship products in the CHD field. Leveraging on the long-term technology accumulation, we have maintained our leading position in the field of CHD interventional therapy through technology upgrading, products iteration and original technology. Medical devices for CHD are the stabilizers for the Group's business, the Group is entering a new phase of rapid growth in its various businesses through extended development while maintaining its traditional strengths.

In line with our technological philosophy of "No Implantation for Intervention", the Group will continue to promote the research and development and promotion of biodegradable material, realizing the clinical application of degradable-related technology in more medical device products.

PFO and LAA Occluder Products

Our first generation cardioembolic stroke prevention products, being LAA occluder and PFO occluder products, were successfully commercialized in 2020 and 2012, respectively.

Our second generation cardioembolic stroke prevention product candidate, being oxide coating PFO occluder, has completed clinical follow-up visits and entered the registration application stage, and is expected to submit NMPA registration application in the third quarter of 2025. The third generation MemoSorb® biodegradable PFO occluder product was approved for marketing in September 2023. The PFO surgeries have a better market foundation and have shown a sign of rapid growth in recent years. Coupled with the Company's innovative biodegradable technology, the products have gained widespread attention and high popularity in the market upon their launch, and have achieved excellent sales results after marketing and clinical application for nearly two years. As of June 30, 2025, cumulative sales of the product have exceeded RMB200 million since its launch, thus becoming another blockbuster product of the Group in the implementation of the philosophy of "Implantation without Residue". It was also a typical example of the Company's innovative products with significant commercialization results. The Company's another important application of the biodegradation technology in cardioembolic stroke area, Bio-Lefort® biodegradable LAA occluder product candidate has successfully completed its pre-clinical type inspection and animal test stages as planned and officially entered the stage of multi-center clinical trial enrollment.

Aortic and Peripheral Occluders

The Company has established a presence in the aortic and peripheral fields, with products including biodegradable aortic occluder, aortic embolization occluder and degradable peripheral occlusion-related products. The occluder used for aortic dissection rupture is an innovative application of biodegradable technology to treat distal rupture of the aortic dissection. Through minimally invasive interventional surgery, the aortic dissection rupture can be precisely sealed, preventing the expansion or rupture of the dissection and at the same time preserving the blood flow of the important blood vessels and improving the blood supply of the remote organs; it also reduces the post-surgical complications and minimizes the risk of the surgery. The aortic embolization occluder is specifically designed to deal with endoleak after endoluminal repair of abdominal aortic aneurysms. It adopts a self-expanding structure with dense mesh weaving (密網編織自膨結構), which can maintain full expansion in the meandering and complex space, efficiently fill the aortic aneurysm, promote thrombosis, effectively reduce the size of the tumor capsule and avoid the risk of rupture. At present, both products have completed type inspection and animal tests, and progressed into the clinical trial stage. Currently, there are no commercially available targeted treatment devices for aortic dissection rupture and postoperative II endoleak after aortic aneurysm repair in the market, and both of the Group's products are global innovations. The biodegradable aortic occluder combines cardiac occluder technology and biodegradable technology, and it is expected to overcome the international challenge of distal rupture of the aortic dissection treatment with accurate occlusion, material innovation and high clinical efficiency as its core competitiveness. The aortic embolization occluder is designed for large abdominal aortic aneurysms, which has the advantages of high pressure-to-compression ratio, high filling efficiency, excellent sheath performance, and simple operation. The two products will provide patients with safer and more effective treatment options, and will have excellent commercialization opportunities and market prospects in the future.

Heart Valve Product Candidates

The Company's products in heart valve field mainly covered aortic valve and mitral valve products. Our ScienCrown® was officially commercialized in early 2025. With its excellent clinical performance and robust evidence-based data, the ScienCrown® fully recyclable self-expanding short valve fully demonstrates the innovative transformation capabilities and clinical advantages of "Intelligently Made in China" in the field of structural heart disease intervention therapy. As the world's first self-expanding short valve combining the advantages of balloon dilation valves, ScienCrown® valve is featured with smooth pre-bending over the arch, release coaxial, stable expansion, good support and 100% recovery under working condition of artificial valve, etc., which could address the pain points of clinical demand in an optimal manner and greatly shorten the surgeon's learning curve, thus bringing a new standard of care to patients and providing a better clinical experience in valve performance and prognosis. In combination with the short valve frame and pre-bent delivery system (預彎輸送系統), it demonstrates excellent adaptability in complex lesions such as severe calcification and biological valve deterioration. Through differentiated competition methods, the Company expects that it will bring safer and better products to clinical-end and generate greater revenue to the Company. To date, the products have been introduced into more than 70 clinical centers in China and their implantations have been conducted. In addition, we are developing a transcatheter aortic valve system for patients with simple aortic regurgitation. The product adds a clamped positioning design to the valve based on the prototype of ScienCrown® TAVR system which is suitable for dual indications of valvular insufficiency and stenosis, and adds a bending function based on the pre-bending feature of the original delivery system to improve operational performance of clamped positioning design. The

product has completed animal tests and type inspection currently and it is planned to carry out clinical trials by the end of 2025. Our transapical mitral valve clip system is currently undergoing phase II clinical trials, and we expect to postpone submission of its registration application to the NMPA until 2026. We conducted independent innovation and optimization in the product design and also drew on the extensive experience from clinicians in respect of transcatheter mitral valve clip system, enabling the design and performance of the product much more acclimated to Chinese patients and the usage habits of Chinese physicians. It is currently in the pre-clinical preparation stage and is about to initiate the clinical trials. Our self-developed TMVR system has completed the implantation in the animal and the follow-up of six months after surgery, accumulating relevant technology and experience.

As an important part of structural heart disease, the field of heart valve therapy is booming in China, and after years of market cultivation, the domestic market has gradually matured and begun to enter the harvest period. With the technological precipitation of aortic valve products that have entered the early stage of commercialization and the accumulation of market resources for related products, the Company will also continue to make efforts in this field and launch more and better product solutions as early as possible.

Mechanical Circulatory Support Products

The Company has expanded into the field of mechanical circulatory support ("**MCS**") devices, which are designed to provide temporary or long-term support to patients requiring cardiac assisted power. The portfolio of our MCS device product line covers both short- and long-term products, which are designed to assist or replace the pumping function of the ventricles. The portfolio of our MCS device product line includes transcatheter ventricular support system, high-risk percutaneous coronary interventions ("**PCI**") ventricular support system, expandable trochanteric ventricular support system and wholeheart support system. In particular, the transcatheter left ventricular support system suitable for left ventricular support is in the pre-clinical type inspection stage, and mass animal tests have been carried out. Supporting peelable sheaths and other interventional accessories with self-developed materials have been designed and entered type inspection stage and bioassay stage. Small diameter transcatheter left ventricular support system and high-risk PCI coronary protection left ventricular support system for patients requiring low-flow support or high-risk PCI patients will progress into the stage of type inspection in the near future. The Company is an early pioneer in the field of MCS in the PRC, which is still emerging in the PRC with a bright market prospect. With the Company's profound research and development capability and technology accumulation in active medical device field, the Company will provide patients in the field with the most optimal medical solutions and is confident that it will become one of the most core and valuable participants in the field.

Pathway Products

Pathway products mainly include CHD occluder products and procedural accessories for heart valve and also include atrial septal radiofrequency puncture products and others.

RF-Lance® radiofrequency puncture devices and RF-Lance® disposable radiofrequency atrial septal puncture needles have been approved for marketing in the PRC in April and July 2024, respectively. The approvals of these two products further enrich the Group's product lines, and the Company has become one of the high-quality suppliers with the most comprehensive product lines in the field of structural heart disease in China.

Occluder related accessory products are important component parts of occlusion surgery. As at the date of this announcement, the Group has owned ten commercially available occluder related procedural accessories, and in line with the increasing commercialization level of occluder products, the accessory products have also achieved considerable revenue. Our biodegradable LAA occluder delivery system has obtained a registration certificate and has been launched for sale in 2025.

The Company owned seven types of valves related procedural accessories, including, among others, balloon dilatation catheter for aortic valve, super stiff guidewire, thrombus protection device and vascular closure device system. In particular, the balloon dilatation catheter for aortic valve has received registration approval from the NMPA at the end of 2024; the super stiff guidewire has been submitted for registration in the fourth quarter of 2024 and is expected to be approved for marketing in the fourth quarter of 2025; vascular closure device system has entered the clinical trial stage, of which the clinical progress has been finished more than a half. The product has an innovative design structure, which can reduce vascular complications and provide physicians with excellent ease-to-use experience. The product is expected to be submitted for registration in the first quarter of 2026.

OUTLOOK

Looking forward, we will continue to be committed to providing safe, effective, innovative and comprehensive medical solutions for patients in pan heart disease-related medical device fields.

We will continue to explore and develop new technologies and focus on the core technologies and product development targeting structural heart diseases to enrich our product portfolio to cover a full range of treatment options for various fields of structural heart disease. Furthermore, we will continue to promote technology in a number of aspects, including design and concept innovation, material innovation, structural design innovation, production process optimization, to further enhance the innovation, functionality and reliability of our products. Meanwhile, we firmly believe that biodegradable technology is one of the important technology applications for medical device products in the future, and will greatly stimulate the structural changes in the domestic medical market and drive the overall transformation and upgrade of the medical device industry as widely applied to our occluder product and other product candidates, which positions us well to capitalize on the significant market opportunities, to further explore existing market and expand into incremental market.

In the CHD interventional devices field, we will leverage our significant market advantages established with more than 20 years of in-depth development to continue to increase the speed of iteration of our innovative products and drive rapid business growth. Meanwhile, we will continue to promote innovative products into overseas markets and have obtained CE certification for the occluders of the third generation oxide coating series, which will further drive international market growth.

In the cardioembolic stroke prevention field, we will explore the research and development of new PFO occlude products and LAA occlude products, while we will continue to promote the commercialization of our marketed products. In particular, the biodegradable PFO product achieved excellent sales results during the Reporting Period. The Company will further enhance interaction and communication with surgeons, strengthen quality control of products and marketing promotion, and endeavor to broaden its sales channels, with a view to further opening up the market for the product over the next few years, so as to enable more patients to enjoy the quality experience and convenience brought by innovative medical device products through surgical treatments and regain healthy living. We believe, upon application of the biodegradable technology to such field, we are well positioned to capitalize on and share the significant potential in the domestic fast-growing and low-penetration market and enable more doctors and patients to enjoy our innovative products and quality services by leveraging our early-mover advantages, excellent product features, and well-established sales channels, which will put us in a leading market competitive position in such field.

In the valve stenosis and reflux therapy field, we will rely on our existing technology platform for valve products, further consolidate and strengthen our technological advantages, continue to promote concept of "Tool Box", and focus on the development of valve products with great medical demand and promising market while covering the full product line of valves. Among them, we will accelerate the progress of research and development of the TMVr-F system and the TMVR system for the treatment of mitral valve regurgitation disease, in order to achieve full coverage of mitral valve disease treatment and address the increasing clinical demands from patients and physicians. We will accelerate the advancement of iterative new products based on ScienCrown® TAVR system for Conformité Européenne ("**CE**") Certificate registration clinical trials, the special dry valve of such iterative products, upon processing by adopting the self-developed technology, has the advantages of stronger anti-calcification ability, better hemodynamic effect and longer service life. We are also developing a transcatheter aortic valve system for patients with simple aortic regurgitation, which will complement the ScienCrown® TAVR system to provide optimal treatment options for patients with different types of aortic valve disease.

Cardiac mechanical circulatory support is a life support technology, and has become an important "bridge" treatment for patients with acute cardiac event and end-stage heart failure after decades of development, which also has more extensive clinical application. It is estimated that approximately 13.7 million patients in China and more than 64 million patients globally suffered from cardiac underpower, and about 50% of them will die within five years after diagnosis. The global market scale of MCS devices is expected to grow at a compound annual growth rate of 10% or above from 2021 to 2028, with a market value expected to reach approximately USD3.4 billion in 2025. The Company, as a cardiovascular interventional medical devices company with strong spirit of technological innovation, has been dedicated to expanding into the blue ocean market of MCS and protective PCI. The Company is developing a series of product candidates, which may help patients, after marketing, significantly improve their quality of life and survival rate. Meanwhile, as a multidisciplinary composite technology, such products will fully demonstrate our technological accumulation, ensure that the Company continues to seize the technological highland in medical devices field, and ensure the progressive development of the Company's future product lines and the sustainable development of the Company's business.

In the structural cardiology pathway products field, we are developing and producing a number of products, and one pathway product has obtained certificates during the Reporting Period. In particular, the Company is one of the early developers of our vascular closure device candidates, and there is no vascular closure device approved for marketing in the PRC. It is estimated that the market size of vascular closure devices in the PRC will have a greater growth, in particular, aortic valve intervention technology has the most mature market and the largest number of patients are those with mitral regurgitation. The market for mitral valve and tricuspid valve interventions will gradually expand, and the demand for large-caliber vascular closure devices will also increase in line with the development of technology. The Company will accelerate the research and development of vascular occluder device products to meet and lead the market demand.

We will strengthen our marketing team building, explore potential marketing channels, continue to expand our sales network in China and continue to build our good reputation and word-of-mouth among doctors and patients. We will continue to strive to promote product brand awareness and influence in the industry and academia, and solidify and strengthen our communication, exchange and interaction with research institutions, hospitals, doctors and KOLs to obtain valuable feedback from them. We will also collect and dive deep into more market data and information, continuously improve and optimize the product design and production process and enhance the service capability of the sales terminal, so as to better serve the doctors and patients with better products and more considerate sales service capability, and strive to become one of the important leaders in marketing and sales service in the PRC.

In terms of overseas business, we will actively expand our overseas sales channels with global insight. With a rigorous, pragmatic and sincere attitude and way of working, we will endeavor to explore the market potential of the existing products and increase the market penetration rate of the existing products, and build up a good reputation of our products and corporate image in the international market, to enhance recognition of Chinese brands and made in China in the global market. We will keep abreast with the development trend, clinical demand and market competition layout in global markets in a timely manner, and formulate a plan for overseas clinical trial and registration in a reasonable manner, to advance the commercialization process of innovative products such as biodegradable occluder series and valve series in overseas markets in due course, which is conducive to a better and sustainable development of the Company's overseas business so as to ensure the smooth implementation of the Company's internationalization strategy and achieving outstanding commercialization results.

FINANCIAL REVIEW

Revenue

Our revenue is mainly derived from the sales of medical devices through distributors and direct sales.

Our revenue increased by 32.4% from RMB249.1 million for the six months ended June 30, 2024 to RMB329.7 million for the six months ended June 30, 2025. The following table sets forth a breakdown of our revenue by major products for the six months ended June 30, 2024 and 2025.

	Six months ended June 30,				
	2025		2024		Change
	RMB	***%***	*RMB*	*%*	*%*
CHD occluder products	**160,628,028.37**	**48.7**	128,570,233.84	51.6	24.9
PFO and LAA occluder products	**81,656,574.20**	**24.8**	79,763,191.28	32.0	2.4
Pathway products	**47,192,209.59**	**14.3**	40,346,197.08	16.2	17.0
Heart valve products	**40,125,415.38**	**12.2**			
Other products	**103,111.24**	**0.0**	420,526.45	0.2	-75.5
Total	**329,705,338.78**	**100.0**	249,100,148.65	100.0	32.4

CHD occluder products

Revenue generated from sales of CHD occluder products was an important component of the Group's revenue, which increased by 24.9% from RMB128.6 million for the six months ended June 30, 2024 to RMB160.6 million for the six months ended June 30, 2025, representing 51.6% and 48.7% of our revenue in the corresponding periods, respectively. Revenue generated from sales of CHD occluder products was able to achieve rapid growth, which was primarily due to the facts that revenue generated from our traditional metal occluder products grew steadily, and MemoSorb® IV biodegradable VSD and ASD occlude products have obtained certificates successfully and commercialized rapidly, resulting in substantial increase in revenue; at the same time, we are also achieving product iteration and differentiated competitive landscape through biodegradable technology.

PFO and LAA occluder products

Revenue generated from sales of PFO and LAA occluder products increased by 2.4% from RMB79.8 million for the six months ended June 30, 2024 to RMB81.7 million for the six months ended June 30, 2025, representing 32.0% and 24.8% of our revenue in the corresponding periods, respectively. The revenue from the product line was mainly derived from the sales of third generation MemoSorb® biodegradable PFO occluder products. Due to innovative incorporation of biodegradable technology, the products have gained widespread attention in the market since their launch in the second half of 2023, and won high popularity and recognition from both clinical applications and patients, which has brought about excellent commercialization results, and the proportion of the product line in total revenue has been increasing gradually.

Pathway products

Revenue generated from sales of our pathway products increased by 17.0% from RMB40.3 million for the six months ended June 30, 2024 to RMB47.2 million for the six months ended June 30, 2025, representing 16.2% and 14.3% of our revenue in the corresponding periods, respectively. Our pathway products primarily include interventional delivery systems and snares mainly related to CHD occluder products. Revenue generated from sales of interventional delivery system was the largest source of our revenue generated from sales of pathway products. The increase was primarily attributable to an increase in the sales volume of our various occluder products, and the sales volume of our related procedural accessories increased accordingly.

Heart valve products

Our ScienCrown® TAVR system and SimoMelon® balloon dilatation catheter for aortic valve received registration approval from the NMPA at the end of 2024 and have officially begun commercialization in early 2025. With the unique structural design, superior product quality and comprehensive sales channels, our heart valve products achieved a significant commercialization result. The products achieved sales revenue of RMB40.1 million for the six months ended June 30, 2025, representing 12.2% of our revenue in the corresponding period. We also believe that as the commercialization process progresses, this proportion will increase rapidly.

Other products

For the six months ended June 30, 2024 and 2025, revenue generated from the sales of other products decreased by 75.5% from RMB0.4 million for the six months ended June 30, 2024 to RMB0.1 million for the six months ended June 30, 2025. The sales of other products primarily included vascular plug and products with relatively low applicability or importance.

Operating cost

Our operating cost increased by 102.2% from RMB22.4 million for the six months ended June 30, 2024 to RMB45.4 million for the six months ended June 30, 2025. Our operating cost primarily consisted of (i) raw materials and consumables; (ii) labor costs; (iii) amortization of intangible assets; (iv) depreciation of property, plant and equipment; (v) transportation costs; (vi) utilities and office expenses; and (vii) others.

The following table sets forth our cost of sales by nature in absolute amounts and as percentages of our total cost of sales for the six months ended June 30, 2024 and 2025.

	Six months ended June 30,				
	2025		2024		Change
	RMB	***%***	*RMB*	*%*	*%*
Raw materials and consumables	**22,644,621.05**	**49.9**	10,133,011.07	45.2	123.5
Labor costs	**8,003,887.50**	**17.6**	5,842,466.37	26.0	37.0
Amortization of intangible assets	**11,998,822.85**	**26.5**	4,222,953.26	18.8	184.1
Depreciation of property, plant and equipment	**851,437.70**	**1.9**	827,572.39	3.7	2.9
Transportation costs	**550,245.83**	**1.3**	743,573.54	3.3	-26.0
Utilities and office expenses	**516,334.57**	**1.1**	408,813.02	1.8	26.3
Others	**792,791.85**	**1.7**	251,885.17	1.1	214.7
Total	**45,358,141.35**	**100.0**	22,430,274.82	100.0	102.2

Our raw materials and consumables costs primarily represented nitinol products, sheathes and other metal and plastic components used during the manufacturing process, which increased by 123.5% from RMB10.1 million for the six months ended June 30, 2024 to RMB22.6 million for the six months ended June 30, 2025, which was primarily attributable to the gradual expansion of the Group's product lines, including the commercialization of heart valve products in early 2025 and their outstanding performance, which resulted in an increase in related costs; the increase in costs of materials for other products due to the increase in output and sales volume.

Our labor costs increased by 37.0% from RMB5.8 million for the six months ended June 30, 2024 to RMB8.0 million for the six months ended June 30, 2025, which was primarily attributable to the increase in output and sales volume of various products, resulting in an increase in labor costs.

Our amortization of intangible assets increased by 184.1% from RMB4.2 million for the six months ended June 30, 2024 to RMB12.0 million for the six months ended June 30, 2025, which was primarily attributable to the transfer of capitalized R&D expenditure of a number of new products developed by us to intangible assets and the commencement of amortization after the products obtained the NMPA approvals and entered the commercialization stage, resulting in a significant increase in our amortization of intangible assets as compared to the corresponding period last year.

For the six months ended June 30, 2024 and 2025, our depreciation of property, plant and equipment remained basically stable at RMB0.83 million and RMB0.85 million, respectively.

Our transportation costs decreased by 26.0% from RMB0.7 million for the six months ended June 30, 2024 to RMB0.6 million for the six months ended June 30, 2025, which was primarily attributable to the change of the logistics service provider with a lower quote by us at the beginning of 2025, resulting in a decrease in our transportation costs.

Our utilities and office expenses increased by 26.3% from RMB0.4 million for the six months ended June 30, 2024 to RMB0.5 million for the six months ended June 30, 2025, which was primarily attributable to the expansion of the Group's production scale, resulting in the increase in related expenses such as utilities and heating, and property rents and property management fees.

Our other costs increased by 214.7% from RMB0.3 million for the six months ended June 30, 2024 to RMB0.8 million for the six months ended June 30, 2025, which was primarily attributable to the expansion of the Group's production scale, resulting in the increase in expenses directly related to production, such as processing fees, testing fees for production environment and fees for sterilization.

Gross profit

Our gross profit increased by 25.4% from RMB226.7 million for the six months ended June 30, 2024 to RMB284.3 million for the six months ended June 30, 2025. The increase in our gross profit was in line with the growth in our overall revenue.

Taxes and surcharges

Our taxes and surcharges primarily include (i) urban maintenance and construction tax; (ii) education surcharge; (iii) local education surcharge; (iv) property tax; (v) stamp duty; and (vi) land use tax. Our taxes and surcharges increased by 52.9% from RMB2.8 million for the six months ended June 30, 2024 to RMB4.3 million for the six months ended June 30, 2025, which was primarily attributable to the expansion of the overall revenue scale of the Company and the increase in business volume, resulting in increases in urban maintenance and construction tax, education surcharge, local education surcharge and stamp duty.

Selling expenses

Our selling expenses primarily included (i) labor costs; (ii) travel and transportation fees; (iii) market fees; (iv) exhibition fees; (v) business entertainment fees; and (vi) business promotion fees. Our selling expenses increased by 37.4% from RMB31.5 million for the six months ended June 30, 2024 to RMB43.3 million for the six months ended June 30, 2025, which was primarily attributable to (i) an increase of RMB5.6 million in labor costs as a result of the Company's business development needs to expand the marketing team and increase marketing personnel and (ii) a total increase of approximately RMB7.2 million in various fees such as market fees, travel and transportation fees and exhibition fees, due to the successful commercialization of several new products of the Company, resulting in the significant increase of marketing activities of the Group.

Administrative expenses

Our administrative expenses primarily consisted of (i) labor costs; (ii) consulting service fees; (iii) share-based payment; (iv) depreciation and amortization expenses; (v) auditor's remuneration; (vi) travel and transportation expenses; and (vii) office expenses, etc. Our administrative expenses decreased by 20.7% from RMB18.4 million for the six months ended June 30, 2024 to RMB14.6 million for the six months ended June 30, 2025. This was primarily attributable to a decrease in consulting service fees of intermediary institutions of RMB1.0 million for the current period as compared to the corresponding period last year.

Research and development expenses

Our research and development expenses primarily consisted of (i) labor costs; (ii) materials, power and manufacturing inspection fees; (iii) depreciation and amortization expenses; (iv) design and clinical trial fees; (v) share-based payment; (vi) outsourced research and development expenses; and (vii) other expenses. Our research and development expenses increased by 17.0% from RMB21.7 million for the six months ended June 30, 2024 to RMB25.4 million for the six months ended June 30, 2025, primarily due to an increase in materials, power and manufacturing inspection fees of RMB1.4 million; and an increase in design and clinical trial fees of RMB1.0 million, as a result of the addition of several new research and development projects in the second half of 2024, which resulted in an increase in the above two expenses for the current period as compared to related expenses of the corresponding period last year.

Financial expenses

Our financial expenses primarily consisted of (i) interest expenses; (ii) interest income; (iii) exchange gains or losses; and (iv) handling charges. Our financial expenses increased by 30.1% from RMB-14.1 million for the six months ended June 30, 2024 to RMB-9.9 million for the six months ended June 30, 2025, primarily due to a decrease in interest income of RMB3.8 million during the Reporting Period as compared to the corresponding period last year due to the continuous decrease in interest rates on various types of domestic deposits.

Loss on impairment of credit

Our loss on impairment of credit primarily represented provision for impairment of accounts receivable and other receivables during the Reporting Period. Our loss on impairment of credit decreased by 66.0% from RMB7.1 million for the six months ended June 30, 2024 to RMB2.4 million for the six months ended June 30, 2025, primarily due to a decrease in the expected credit loss rate of accounts receivable and a period-on-period decrease in the provision for impairment of credit calculated accordingly as a result of the optimization of aging structure of the Group's accounts receivable.

Income tax expenses

Our income tax expenses increased by 20.2% from RMB23.9 million for the six months ended June 30, 2024 to RMB28.7 million for the six months ended June 30, 2025, which was primarily attributable to the increase in taxable income as a result of the increase in the Company's results.

Net profit

As a result of the foregoing, our net profit for the Reporting Period increased by 29.8% from RMB140.2 million for the six months ended June 30, 2024 to RMB182.0 million for the six months ended June 30, 2025.

LIQUIDITY, FINANCIAL RESOURCES AND CAPITAL STRUCTURE

The primary uses of cash are to fund the daily operations of the business of the Group. For the six months ended June 30, 2025, the Group principally used cash generated from its operating and financing activities and net proceeds from the Global Offering to meet its demand of capital expenditures and working capital. Going forward, the Company believes that its liquidity requirements will be satisfied with a combination of cash flows generated from our operating activities and other funds raised from the capital markets from time to time. As of June 30, 2025, the Group had not used any financial instruments for hedging purposes.

Cash flows

As of June 30, 2025, our cash and cash equivalents were denominated in RMB, HK dollar, USD and Euro dollars. Our total cash and cash equivalents increased by 17.8% from RMB1,121.3 million as of December 31, 2024 to RMB1,321.1 million as of June 30, 2025, which was primarily attributable to the net cash generated from operating activities of RMB166.8 million, resulting in an increase in cash and cash equivalents at the end of the Reporting Period.

Borrowings

As of June 30, 2024 and 2025, we had no outstanding balance of borrowings or unutilized banking facilities.

Net current assets

Our net current assets decreased by 0.9% from RMB1,333.0 million as of December 31, 2024 to RMB1,321.2 million as of June 30, 2025. Our net current assets position as of the above dates was mainly attributable to our cash at bank and on hand, accounts receivable, inventories, prepayments, other receivables and certificates of deposit due within one year, partially offset by our accounts payable, contract liabilities, other payables, employee benefits payable, taxes payable and lease liabilities due within one year. The decrease in our net current assets was primarily attributable to an increase in the closing balance of other payables of RMB215.5 million as of June 30, 2025 as a result of the declaration of final dividend for 2024, an increase in cash at bank and on hand and certificates of deposit due within one year of RMB142.9 million in aggregate, an increase in accounts receivable of RMB38.7 million, and an increase in prepayments of RMB13.6 million, a combination of which caused a slight decrease in the net current assets.

Material Acquisitions and Disposals and Significant Investments

We did not have any material acquisitions and disposals and significant investments during the six months ended June 30, 2025.

Pledge of Assets

As of June 30, 2025, we did not pledge any of our assets.

Future Plans for Material Investments or Capital Asset

Save as disclosed in the section headed "Use of Net Proceeds from Listing" in this announcement and the section headed "Future Plans and Use of Proceeds" in the Prospectus, we did not have detailed future plans for material investments or capital assets.

Capital Expenditure

Our total capital expenditure increased by 30.4% from approximately RMB31.0 million for the six months ended June 30, 2024 to approximately RMB40.4 million for the six months ended June 30, 2025. Our capital expenditure primarily included our purchase of equipment, purchase of intangible assets and payment for research and development expenses of capitalization. We funded these expenditures with cash generated from our operating and financing activities.

Capital Commitments

Our capital commitments decreased from approximately RMB19.2 million as of December 31, 2024 to approximately RMB3.3 million as of June 30, 2025, primarily in connection with purchase of equipment, licensing of product technologies and right of commercialization of products.

Contingent Liabilities

As of June 30, 2025, we did not have any material contingent liabilities.

Foreign Exchange Risk Management

Our functional currency is RMB. Foreign exchange risk arises when future commercial transactions or recognized assets and liabilities are denominated in a currency that is not our functional currency. We expose ourselves to foreign exchange risk because certain of our accounts payable, accounts receivable and cash at bank and on hand are denominated in foreign currencies. We will mitigate such a risk by constantly reviewing the economic situation and foreign exchange risk, and applying hedging measures when necessary.

Employee and Remuneration Policy

As of June 30, 2025, we had 374 full-time employees (December 31, 2024: 314), all of whom were based in China. The total staff costs for the six months ended June 30, 2025 (including staff remuneration, bonuses, welfare cost and social insurance fees etc.) amounted to approximately RMB55.4 million (including those capitalized staff costs of approximately RMB6.3 million).

We primarily recruit our employees through recruitment agencies, internal referrals and online recruiting channels, including our corporate website, job search websites and social networking platforms. We have adopted training protocols, pursuant to which we provide on-board and regular continuing trainings for our employees. As part of our human resources strategy, we offer employees competitive salaries, performance-based cash bonuses and other incentives.

Indebtedness

The following table sets forth the breakdown of our lease liabilities as of the dates indicated:–

	June 30, 2025	December 31, 2024
	RMB	*RMB*
	(Unaudited)	(Audited)
Lease liabilities	**1,146,614.66**	1,513,992.96

Key Financial Ratios

The following table sets forth our key financial ratios for the period/year indicated:–

	June 30, 2025	December 31, 2024
Liquidity ratio		
Current ratio	**5.3 times**	16.8 times
Gearing ratio	**13.4%**	4.1%

(1) The calculation of current ratio is based on current assets divided by current liabilities as of the end of the period/year.

(2) The gearing ratio is calculated based on the Group's total liabilities divided by total assets as of the end of the period/year.

Current ratio

Our current ratio was 5.3 times and 16.8 times as of June 30, 2025 and December 31, 2024, respectively. The decrease in current ratio was primarily due to the change in current assets and current liabilities as discussed in the section headed "Net current assets".

CONSOLIDATED BALANCE SHEET

(All amounts in RMB Yuan unless otherwise stated)

Assets	*Note*	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Current assets:			
Cash at bank and on hand		**1,323,679,495.53**	1,125,405,765.25
Settlement reserve			
Lending funds			
Financial assets held-for-trading			
Derivative financial assets			
Notes receivable			
Accounts receivable	*III*	**109,033,399.92**	70,327,733.16
Receivable financing			
Prepayments		**33,617,724.70**	20,033,452.39
Insurance premium receivable			
Reinsurance premium receivable			
Reserves for reassurance contracts receivable			
Other receivables		**6,694,043.25**	1,907,952.60
Financial assets purchased under agreements to resell			
Inventories		**96,491,122.21**	87,241,588.03
Including: Data resources			
Contract assets			
Assets held for sale			
Non-current assets due within one year		**52,595,875.17**	107,974,139.89
Other current assets		**3,281,466.98**	4,531,884.50
Total current assets		**1,625,393,127.76**	1,417,422,515.82

Assets	*Note*	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Non-current assets:			
Loans and advances granted			
Debt investments			
Other debt investments			
Long-term receivables			
Long-term equity investments			
Investments in other equity instruments			
Other non-current financial assets			
Investment properties		**7,341,505.11**	7,451,830.95
Fixed assets	*IV*	**113,323,533.49**	116,567,671.35
Construction in progress		**2,269,002.24**	
Productive biological assets			
Oil and gas assets			
Right-of-use assets		**3,435,947.68**	4,051,871.92
Intangible assets		**241,046,312.68**	250,636,543.43
Including: Data resources			
Development expenses		**153,372,652.62**	137,060,996.47
Including: Data resources			
Goodwill		**48,281,830.04**	48,281,830.04
Long-term deferred expenses			190,417.80
Deferred income tax assets		**11,897,503.12**	12,787,218.28
Other non-current assets		**72,706,103.60**	88,580,534.26
Total non-current assets		**653,674,390.58**	665,608,914.50
Total assets		**2,279,067,518.34**	2,083,031,430.32

Liabilities and owners' equity	*Note*	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Current liabilities:			
Short-term borrowings			
Loans from central bank			
Placements from banks and other financial institutions			
Financial liabilities held-for-trading			
Derivative financial liabilities			
Notes payable			
Accounts payable	*V*	**25,630,824.83**	31,393,102.65
Advances from customers			
Contract liabilities	*VI*	**15,218,576.27**	15,068,531.19
Securities sold under agreements to repurchase			
Deposits from customers and interbanks			
Receiving from vicariously traded securities			
Receiving from vicariously sold securities			
Employee benefits payable		**4,289,290.45**	9,104,354.88
Taxes payable		**33,284,412.59**	18,798,067.87
Other payables	*VII*	**223,204,071.62**	7,668,902.54
Fee and commission payable			
Reinsured accounts payable			
Liabilities held for sale			
Non-current liabilities due within one year		**2,168,083.30**	2,056,734.65
Other current liabilities		**414,857.86**	332,670.74
Total current liabilities		**304,210,116.92**	84,422,364.52

Liabilities and owners' equity	*Note*	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Non-current liabilities:			
Reserve fund for insurance contracts			
Long-term borrowings			
Bonds payable			
Including: Preference shares			
Perpetual bonds			
Lease liabilities		**1,146,614.66**	1,513,992.96
Long-term payable		**526,887.00**	
Long-term employee benefits payable			
Estimated liabilities			
Deferred income			
Deferred income tax liabilities			45,675.04
Other non-current liabilities			
Total non-current liabilities		**1,673,501.66**	1,559,668.00
Total liabilities		**305,883,618.58**	85,982,032.52

Liabilities and owners' equity	*Note*	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Owners' equity:			
Share capital		**346,749,997.00**	346,749,997.00
Other equity instruments			
Including: Preference shares			
Perpetual bonds			
Capital reserve		**1,340,628,573.36**	1,331,533,364.64
Less: Treasury shares			
Other comprehensive income			
Special reserve			
Surplus reserve			
Provision for general risks			
Retained earnings		**285,805,329.40**	318,766,036.16
Total equity attributable to shareholders of the Company		**1,973,183,899.76**	1,997,049,397.80
Non-controlling interests			
Total owners' equity		**1,973,183,899.76**	1,997,049,397.80
Total liabilities and owners' equity		**2,279,067,518.34**	2,083,031,430.32

CONSOLIDATED INCOME STATEMENT

(All amounts in RMB Yuan unless otherwise stated)

Item		Note	Six months ended June 30, 2025 (Unaudited)	2024 (Audited)
I.	Total operating income		**329,705,338.78**	249,100,148.65
	Including: Operating income	*VIII*	**329,705,338.78**	249,100,148.65
	Interest income			
	Premium earned			
	Income for handling charges and commissions			
II.	Total operating cost		**123,008,408.82**	82,695,713.46
	Including: Operating cost	*VIII*	**45,358,141.35**	22,430,274.82
	Interest expense			
	Handling charges and commissions			
	Refunded premiums			
	Net amount of compensation payout			
	Net amount withdrawn for insurance contract reserves			
	Policy dividend expense			
	Reinsured expense			
	Taxes and surcharges		**4,311,640.12**	2,819,277.61
	Selling expenses		**43,250,901.44**	31,485,870.27
	Administrative expenses		**14,605,208.57**	18,413,535.52
	Research and development expenses		**25,354,837.54**	21,671,903.41
	Financial expenses		**-9,872,320.20**	-14,125,148.17
	Including: Interest expenses		**74,169.07**	85,408.45
	Interest income		**9,500,904.56**	13,278,075.95
	Add: Other income		**3,895,091.04**	953,389.05
	Investment income (loss expressed with "-")		**2,606,905.31**	2,056,166.79
	Including: Income from investment in associates and joint ventures			
	Gains from derecognition of financial assets measured at amortised cost			
	Exchange gain (loss expressed with "-")			
	Net exposure hedging benefits (loss expressed with "-")			
	Gains from change in fair value (loss expressed with "-")			1,601,780.81

Item		Note	Six months ended June 30, 2025 (Unaudited)	2024 (Audited)
	Loss on impairment of credit (loss expressed with "-")		**-2,425,491.73**	-7,126,924.40
	Loss on impairment of assets (loss expressed with "-")			
	Gains from disposal of asset (loss expressed with "-")			
III.	Operating profit (loss expressed with "-")		**210,773,434.58**	163,888,847.44
	Add: Non-operating income			251,841.94
	Less: Non-operating expenses		**5,609.34**	3,478.52
IV.	Total profit before tax (total loss expressed with "-")		**210,767,825.24**	164,137,210.86
	Less: Income tax expense	*IX*	**28,743,533.86**	23,908,744.48
V.	Net profit (net loss expressed with "-")		**182,024,291.38**	140,228,466.38
	(I) Classified by continuity of operations			
	1. Net profit from continuing operations (net loss expressed with "-")		**182,024,291.38**	140,228,466.38
	2. Net profit from discontinued operations (net loss expressed with "-")			
	(II) Classified by ownership			
	1. Net profit attributable to shareholders of the parent company (net loss expressed with "-")		**182,024,291.38**	140,228,466.38
	2. Net profit attributable to non-controlling interests (net loss expressed with "-")			
VI.	Net other comprehensive income after tax			
	Net other comprehensive income after tax attributable to shareholders of the Company			
	(I) Other comprehensive income that may not be subsequently reclassified to profit and loss			
	1. Change in remeasurement of defined benefit plans			
	2. Share of other comprehensive income accounted for using equity method that will not be reclassified to profit or loss			
	3. Change in fair value of investments in other equity instruments			
	4. Changes in fair value of credit risks of the Company			

Item		Note	Six months ended June 30, 2025 (Unaudited)	2024 (Audited)
	(II) Other comprehensive income that will be subsequently reclassified to profit or loss			
	1. Share of other comprehensive income accounted for using equity method that will be reclassified to profit or loss			
	2. Change in fair value of other debt investments			
	3. Amount of financial assets reclassified into other comprehensive income			
	4. Provision for credit impairment of other debt investments			
	5. Cash flow hedging reserve			
	6. Exchange differences arising from translation of foreign currency financial statements			
	7. Others			
	Net other comprehensive income attributable to non-controlling interests after tax			
VII.	Total comprehensive income		**182,024,291.38**	140,228,466.38
	Total comprehensive income attributable to shareholders of the Company		**182,024,291.38**	140,228,466.38
	Total comprehensive income attributable to non-controlling interests			
VIII.	Earnings per share:			
	(I) Basic earnings per share (RMB/share)	*X*	**0.5249**	0.4044
	(II) Diluted earnings per share (RMB/share)	*X*	**0.5249**	0.4044

NOTES

(All amounts in RMB Yuan unless otherwise stated)

I. BASIC INFORMATION OF THE COMPANY

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (referred to as "**the Company**" or "**the Group**") was established as a joint-stock company in January 2021 and subsequently listed on the Main Board of The Stock Exchange of Hong Kong Limited in November 2022. As an investment holding company, the Company and its subsidiaries are principally engaged in manufacturing and sales of interventional treatment series occluders for defective congenital heart disease (缺損性先天性心臟病介入治療系列封堵器) and the research and development of biological valve (生物瓣膜) for heart disease.

As of June 30, 2025, the Company's cumulative issued share capital totaled 346,749,997 shares.

Social credit code: 91310000MA1FL7PF84.

Registered address: Room 201, Building 41, No. 258 Xinzhuan Road, Xinqiao Town, Songjiang District, Shanghai.

Parent company of the Company: Lepu Medical Technology (Beijing) Co., Ltd.

II. BASIS OF PREPARATION FOR THE FINANCIAL STATEMENTS

(1) Basis of preparation

The Group prepares financial statements on a going concern basis, based on actual transactions and events, in accordance with the relevant provisions of *China Accounting Standard for Business Enterprises No. 32 – Interim Financial* Report issued by the Ministry of Finance, as well as the disclosure requirements of the *Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited* and the *Hong Kong Companies Ordinance*.

The notes to the interim financial statements are appropriately simplified relative to the notes to the annual financial statements and do not include all information and disclosures presented in the annual financial statements. These interim financial statements should be read in conjunction with the financial statements for the year 2024 prepared by the Group.

(2) Going concern

There are no material matters affecting the Group's ability to continue as a going concern, and there are no material concerns about the Group's ability to continue as a going concern in the next 12 months.

III. ACCOUNTS RECEIVABLE

1. Accounts receivable based on their entry dates shown by ageing

Ageing	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Within 1 year	**116,105,614.04**	80,628,030.36
1-2 years	**5,965,198.05**	311,886.00
2-3 years		311,693.93
3-4 years	**322,525.65**	63,431.86
4-5 years	**64,230.00**	11,630.00
Over 5 years	**3,941,578.65**	3,941,578.65
Sub-total	**126,399,146.39**	85,268,250.80
Less: Provision for bad debts	**17,365,746.47**	14,940,517.64
Total	**109,033,399.92**	70,327,733.16

Note: The Group generally does not offer any official contractual credit terms to its customers and will closely monitor the settlement pattern of respective customers. For certain individual customers with long-term relationship with the Group and have good credit history in the past, the Group may allow them to settle the related receivable balances within a discretionary period ranging from 30 days to 360 days.

2. Accounts receivable by method of bad debt provision

	As at June 30, 2025 (Unaudited)					As at December 31, 2024 (Audited)				
	Book balance		**Provision for bad debts**			Book balance		Provision for bad debts		
Type	**Amount**	**Percentage (%)**	**Amount**	**Percentage (%)**	**Carrying Value**	Amount	Percentage (%)	Amount	Percentage (%)	Carrying Value
Provision for bad debts made on an individual basis										
Provision for bad debts made on a grouping basis by credit risk characteristics	**126,399,146.39**	**100.00**	**17,365,746.47**	**13.74**	**109,033,399.92**	85,268,250.80	100.00	14,940,517.64	17.52	70,327,733.16
Including:										
Expected credit loss on a grouping basis	**121,021,536.02**	**95.75**	**17,365,746.47**	**14.35**	**103,655,789.55**	78,010,032.47	91.49	14,940,517.64	19.15	63,069,514.83
Related party on a grouping basis	**5,377,610.37**	**4.25**			**5,377,610.37**	7,258,218.33	8.51			7,258,218.33
Total	**126,399,146.39**	**100.00**	**17,365,746.47**		**109,033,399.92**	85,268,250.80	100.00	14,940,517.64		70,327,733.16

IV. FIXED ASSETS

1. Fixed assets and disposal of fixed assets

Item	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Fixed assets	**113,323,533.49**	116,567,671.35
Disposal of fixed assets		
Total	**113,323,533.49**	116,567,671.35

2. Breakdown of fixed assets

Item		Buildings	Machinery and equipment	Transportation vehicle	Electronic equipment and others	Total
1.	Original carrying amount					
	(1) As at December 31, 2024 (Audited)	104,450,615.43	56,345,949.22	2,333,970.77	4,961,442.22	168,091,977.64
	(2) Increase during this period		423,902.08		211,828.42	635,730.50
	– Purchase		423,902.08		211,828.42	635,730.50
	(3) Decrease during this period		54,029.48		4,614.53	58,644.01
	– Disposal or retirement		54,029.48		4,614.53	58,644.01
	(4) As at June 30, 2025 (Unaudited)	104,450,615.43	56,715,821.82	2,333,970.77	5,168,656.11	168,669,064.13
2.	Accumulated depreciation					
	(1) As at December 31, 2024 (Audited)	25,212,992.08	20,956,495.02	1,793,755.23	3,561,063.96	51,524,306.29
	(2) Increase during this period	1,226,447.08	2,313,114.16	113,884.56	223,490.36	3,876,936.16
	– Provision made	1,226,447.08	2,313,114.16	113,884.56	223,490.36	3,876,936.16
	(3) Decrease during this period		51,328.01		4,383.80	55,711.81
	– Disposal or retirement		51,328.01		4,383.80	55,711.81
	(4) As at June 30, 2025 (Unaudited)	26,439,439.16	23,218,281.17	1,907,639.79	3,780,170.52	55,345,530.64
3.	Provision for impairment					
	(1) As at December 31, 2024 (Audited)					
	(2) Increase during this period					
	– Provision made					
	(3) Decrease during this period					
	– Disposal or retirement					
	(4) As at June 30, 2025 (Unaudited)					
4.	Carrying value					
	(1) Net book value at June 30, 2025 (Unaudited)	78,011,176.27	33,497,540.65	426,330.98	1,388,485.59	113,323,533.49
	(2) Net book value at December 31, 2024 (Audited)	79,237,623.35	35,389,454.20	540,215.54	1,400,378.26	116,567,671.35

V. ACCOUNTS PAYABLE

1. Accounts payable based on their entry dates shown by ageing

Item	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Within one year (inclusive)	**23,730,174.79**	29,552,201.54
1-2 years	**1,512,206.78**	1,070,796.19
2-3 years	**12,885.02**	623,173.34
Over 3 years	**375,558.24**	146,931.58
Total	**25,630,824.83**	31,393,102.65

Note: The credit period granted by suppliers to the Group ranged from 30 days to 120 days.

VI. CONTRACT LIABILITIES

Item	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Within one year (inclusive)	**15,218,576.27**	13,430,997.04
1-2 years		1,637,534.15
Total	**15,218,576.27**	15,068,531.19

VII. OTHER PAYABLES

Item	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Interest payable		
Dividends payable	**214,984,998.14**	
Other payables	**8,219,073.48**	7,668,902.54
Total	**223,204,071.62**	7,668,902.54

1. Dividends payable

Item	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Dividends for ordinary shares	**214,984,998.14**	
Total	**214,984,998.14**	

2. Other payables

(1) Other payables by nature

Item	**As at June 30, 2025 (Unaudited)**	As at December 31, 2024 (Audited)
Guarantee deposit	**649,800.27**	469,800.27
Current payments	**3,543,736.29**	5,410,768.28
Others	**4,025,536.92**	1,788,333.99
Total	**8,219,073.48**	7,668,902.54

VIII. OPERATING INCOME AND OPERATING COST

1. Breakdown of operating income and operating cost

	Six months ended June 30,			
	2025 (Unaudited)		2024 (Audited)	
Item	**Revenue**	**Cost**	Revenue	Cost
Principal business	**329,626,352.46**	**45,247,815.51**	248,790,984.67	22,209,623.20
Other businesses	**78,986.32**	**110,325.84**	309,163.98	220,651.62
Total	**329,705,338.78**	**45,358,141.35**	249,100,148.65	22,430,274.82

2. Information on the breakdown of operating income and operating cost

Item	Six months ended June 30, 2025 (Unaudited) Operation income	Operating cost	2024 (Audited) Operation income	Operating cost
Classification by product:				
Congenital heart disease occluder products	**160,628,028.37**	**10,325,081.79**	128,570,233.84	7,728,049.14
Pathway products	**47,192,209.59**	**14,841,623.70**	40,346,197.08	11,368,559.76
Patent foramen ovale and left atrial appendage occluder products	**81,656,574.20**	**5,982,853.14**	79,763,191.28	3,090,256.46
Valve products	**40,125,415.38**	**14,090,109.88**		
Others	**103,111.24**	**118,472.83**	420,526.45	243,409.46
Total	**329,705,338.78**	**45,358,141.35**	249,100,148.65	22,430,274.82

IX. INCOME TAX EXPENSE

Item	Six months ended June 30, 2025 (Unaudited)	2024 (Audited)
Current income tax expenses	**27,899,493.74**	24,157,890.78
Deferred tax expenses	**844,040.12**	-249,146.30
Total	**28,743,533.86**	23,908,744.48

X. EARNINGS PER SHARE

1. Basic earnings per share

Basic earnings per share is calculated by dividing the combined net profit attributable to shareholders of ordinary shares of the parent company by the weighted average number of ordinary shares of the Company in issue:

Item	Six months ended June 30, 2025 (Unaudited)	2024 (Audited)
Combined net profit attributable to shareholders of ordinary shares of the parent company	**182,024,291.38**	140,228,466.38
Weighted average number of ordinary shares of the Company in issue	**346,749,997.00**	346,749,997.00
Basic earnings per share	**0.5249**	0.4044
Including: Basic earnings per share from continuing operations	**0.5249**	0.4044
Basic earnings per share from discontinued operations		

2. Diluted earnings per share

Diluted earnings per share is the same as basic earnings per share as there were no potential dilutive ordinary shares outstanding during the six months ended June 30, 2025 and 2024.

OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares, if any) during the six months ended June 30, 2025.

As at June 30, 2025, the Company did not hold any treasury shares.

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this announcement, there are no any material subsequent events undertaken by the Group after June 30, 2025 and up to the date of this announcement.

USE OF NET PROCEEDS FROM LISTING

The Shares were listed on the Stock Exchange on the Listing Date. The net proceeds received from the Global Offering (after deducting the estimated underwriting commissions and other fees and expenses payable by the Company in connection with the Global Offering) was approximately HK$567.3 million.

The following table sets forth the planned use and actual use of the net proceeds from the Global Offering as of June 30, 2025:

Use of Proceeds	**Net proceeds from the Global Offering** *(HK$ million)*	**Unutilized amount as of January 1, 2025** *(HK$ million)*	**Utilized amount from January 1, 2025 to June 30, 2025** *(HK$ million)*	**Unutilized amount as of June 30, 2025** *(HK$ million)*	**Expected timeline for fully utilizing the unutilized amount**[(1)]
To fund our research and development activities	287.6	140.2	19.3	120.9	Before December 31, 2027
For our sales and marketing activities	137.9	103.8	17.4	86.4	Before December 31, 2027
To expand our production capacity and strengthen our manufacturing capabilities	28.4	18.9	7.0	11.9	Before December 31, 2027
To fund potential strategic investments and acquisitions	56.7	43.7	18.6	25.1	Before December 31, 2027
For our working capital and general corporate purposes	56.7	45.9	6.6	39.3	Before December 31, 2027
Total	567.3	352.5	68.9	283.6	

Note:

(1) The expected timeline for fully utilizing the unutilized amount disclosed above is based on the best estimates made by the Board pursuant to the latest information up to the date of this announcement.

As disclosed on pages 485 to 492 of the Prospectus, based on the current business plan, the Company intended to implement the use of proceeds from the Global Offering in the five financial years from 2023 to 2027. The Board currently expects full utilization of the net proceeds raised from the Global Offering by December 31, 2027, subject to changes in light of the Company's evolving business needs and changing market conditions.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company's corporate governance practices are based on the principles and code provisions as set out in the CG Code contained in Appendix C1 to the Listing Rules and the Company has adopted the CG Code as its own code of corporate governance.

Throughout the Reporting Period, the Company has complied with the code provisions as set out in the CG Code, except for the deviation from the below code provisions.

Pursuant to code provision C.2.1 in the CG Code as set out in Appendix C1 to the Listing Rules, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Ms. Chen Juan (陳娟) is currently serving as the chairman of the Board as well as the chief executive officer of the Company. She has been primarily involved in developing overall corporate and business strategies of our Group and making significant business and operational decisions of our Group. Our Directors consider that vesting the roles of both the chairman of the Board and the chief executive officer of the Company in Ms. Chen is beneficial to the business prospects of the Group by ensuring consistent leadership to the Group as well as prompt and effective decision making and implementation. In addition, our Directors believe that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (1) decision to be made by our Board requires approval by at least a majority of our Directors; (2) Ms. Chen and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require, among other things, that she acts for the benefit and in the best interests of our Company and will make decisions for our Company accordingly; (3) the balance of power and authority is ensured by the operations of the Board, which consists of one executive Director, three non-executive Directors and three independent non-executive Directors, and has a fairly strong independence element; and (4) the overall strategic and other key business, financial, and operational policies of our Company are made collectively after thorough discussion at both Board, and senior management levels.

The Board shall nevertheless review the structure and composition of the Board from time to time in light of prevailing circumstances, to maintain a high standard of corporate governance practices of the Company.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding the transactions of securities of the Company by its Directors, supervisors and the relevant employees who would likely possess inside information of the Company. Specific enquiry has been made to all Directors and supervisors of the Company and all of them have confirmed that they have complied with the Model Code during the six months ended June 30, 2025.

AUDIT COMMITTEE

The Audit Committee comprises two independent non-executive Directors, namely Ms. Chan Ka Lai Vanessa and Mr. Zheng Yufeng, and one non-executive Director, namely Mr. Zhu Guanfu.

The Audit Committee has reviewed the unaudited interim financial information of the Group for the six months ended June 30, 2025 together with the Group's auditor, BDO China Shu Lun Pan Certified Public Accountants LLP, and have discussed with the management the accounting principles and practices adopted by the Group and its internal controls and financial reporting matters.

SCOPE OF WORK OF BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP

The figures in respect of the Group's unaudited interim financial information and the related notes thereto for the six months ended June 30, 2025 as set out in the announcement have been reviewed by the Group's auditor, BDO China Shu Lun Pan Certified Public Accountants LLP.

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025 (six months ended June 30, 2024: nil).

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND THE INTERIM REPORT

This announcement was published on the website of the Stock Exchange (www.hkexnews.hk) and on the website of the Company (www.scientechmed.com). The interim report for the six months ended June 30, 2025 will be published on the websites of the Stock Exchange and the Company in due course.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

"ASD"	atrial septal defect, a remnant opening, or a defect, between the left and right atria resulting from the abnormal development, absorption and fusion of the atrial septum during embryonic development
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors of the Company
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"CHD"	congenital heart disease, the formation of the heart and blood vessels during embryonic development or abnormal development or failure to close the channels that should be automatically closed after birth, resulting in abnormalities in the solid structure or function of the blood vessels in the heart or thoracic cavity
"Company"	LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司), a joint stock limited liability company established in the PRC on January 29, 2021 and whose Shares are listed on the Main Board of the Stock Exchange
"Director(s)"	the director(s) of the Company
"FIM"	First in man
"Global Offering"	has the meaning ascribed to it under the Prospectus
"Group", "we", "us", or "our"	the Company and its subsidiaries from time to time
"HK dollar" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"KOLs"	key opinion leaders, who are professionals that influence their peers' medical practice, including but not limited to prescribing behavior
"LAA"	left atrial appendage, a long, narrow and curved blind-end structure extending forward and downward along the anterior wall of the left atrium, which has active diastolic and secretory functions

"Lepu Medical"	Lepu Medical Technology (Beijing) Co., Ltd.# (樂普(北京)醫療器械股份有限公司), a company listed on the ChiNext Board of the Shenzhen Stock Exchange, stock code: 300003, one of our Controlling Shareholders
"Listing Date"	November 8, 2022, being the date on which the Shares of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司) were listed on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Main Board"	the Main Board of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules
"NMPA"	the National Medical Products Administration of the PRC (國家藥品監督管理局), formerly known as the China Food and Drug Administration
"PDA"	patent ductus arteriosus, a remnant opening of the ductus arteriosus, which fails to close normally in one year after birth
"PFO"	patent foramen ovale, a remnant opening of the fetal foramen ovale, which fails to close normally in one year after birth
"PRC" or "China"	the People's Republic of China, excluding, for the purposes of this announcement, Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan
"Prospectus"	the prospectus issued by the Company on October 27, 2022 in connection with the Hong Kong public offering of the Shares
"Reporting Period"	six months from January 1, 2025 to June 30, 2025
"RMB"	Renminbi, the lawful currency of the PRC
"Shareholder(s)"	holder(s) of Share(s)
"Shares"	ordinary share(s) in the share capital of the Company with a par value of RMB1.00 each
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"TAVR"	transcatheter aortic valve replacement, a catheter-based technique to implant a new aortic valve in a minimally invasive procedure that does not involve open-chest surgery to correct severe aortic stenosis

"TMVR"	transcatheter mitral valve repair, which provides a newer, minimally invasive option for treating the most common form of mitral valve leakage for people who cannot undergo open-heart surgery. It is implanted via a tri-axial transcatheter technique and involves suturing together the anterior and posterior mitral valve leaflets
"TMVr-F"	transfemoral mitral valve clip repair, a catheter-based technique to repair the mitral valve in an interventional therapy that does not involve open-chest surgery
"US$" or "USD"	United States dollars, the lawful currency of the United States of America
"VSD"	ventricular septal defect, a defect, or a hole, in the septum between the left and right ventricles of the heart, which may lead to abnormal blood circulation and pulmonary hypertension and other complications in severe cases
"%"	per cent

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
August 22, 2025

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director; Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors; and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.".*

For identification purposes only